Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease
Raket, Lars Lau LU
; Oudin Åström, Daniel
LU
; Norlin, Jenny M.
; Kellerborg, Klas
; Martinez-Martin, Pablo
and Odin, Per
LU
(2022)
In Scientific Reports
12(1).
- Abstract
Parkinson’s disease (PD) is typically considered an age-related disease, but the age at disease onset can vary by decades between patients. Aging and aging-associated diseases can affect the movement system independently of PD, and advanced age has previously been proposed to be associated with a more severe PD phenotype with accelerated progression. In this work, we investigated how interactions between PD progression and aging affect a wide range of outcomes related to PD motor and nonmotor symptoms as well as Health Related Quality of Life (HRQoL) and treatment characteristics. This population-based cohort study is based on 1436 PD patients from southern Sweden followed longitudinally for up to approximately 7.5 years from enrollment... (More)
Parkinson’s disease (PD) is typically considered an age-related disease, but the age at disease onset can vary by decades between patients. Aging and aging-associated diseases can affect the movement system independently of PD, and advanced age has previously been proposed to be associated with a more severe PD phenotype with accelerated progression. In this work, we investigated how interactions between PD progression and aging affect a wide range of outcomes related to PD motor and nonmotor symptoms as well as Health Related Quality of Life (HRQoL) and treatment characteristics. This population-based cohort study is based on 1436 PD patients from southern Sweden followed longitudinally for up to approximately 7.5 years from enrollment (3470 visits covering 2285 patient years, average follow-up time 1.7 years). Higher age at onset was generally associated with faster progression of motor symptoms, with a notable exception of dyskinesia and other levodopa-associated motor fluctuations that had less severe trajectories for patients with higher age at onset. Mixed results were observed for emergence of non-motor symptoms, while higher age at onset was generally associated with worse HRQoL trajectories. Accounting for these identified age-associated differences in disease progression could positively impact patient management and drug development efforts.
(Less)
- author
- Raket, Lars Lau
LU
; Oudin Åström, Daniel
LU
; Norlin, Jenny M.
; Kellerborg, Klas
; Martinez-Martin, Pablo
and Odin, Per
LU
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scientific Reports
- volume
- 12
- issue
- 1
- article number
- 526
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:35017548
- scopus:85122812500
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-021-04356-8
- language
- English
- LU publication?
- yes
- id
- 17bc5fdc-70ab-4f7f-8392-abac28743fe4
- date added to LUP
- 2022-03-01 10:36:29
- date last changed
- 2024-04-18 06:33:01
@article{17bc5fdc-70ab-4f7f-8392-abac28743fe4,
abstract = {{<p>Parkinson’s disease (PD) is typically considered an age-related disease, but the age at disease onset can vary by decades between patients. Aging and aging-associated diseases can affect the movement system independently of PD, and advanced age has previously been proposed to be associated with a more severe PD phenotype with accelerated progression. In this work, we investigated how interactions between PD progression and aging affect a wide range of outcomes related to PD motor and nonmotor symptoms as well as Health Related Quality of Life (HRQoL) and treatment characteristics. This population-based cohort study is based on 1436 PD patients from southern Sweden followed longitudinally for up to approximately 7.5 years from enrollment (3470 visits covering 2285 patient years, average follow-up time 1.7 years). Higher age at onset was generally associated with faster progression of motor symptoms, with a notable exception of dyskinesia and other levodopa-associated motor fluctuations that had less severe trajectories for patients with higher age at onset. Mixed results were observed for emergence of non-motor symptoms, while higher age at onset was generally associated with worse HRQoL trajectories. Accounting for these identified age-associated differences in disease progression could positively impact patient management and drug development efforts.</p>}},
author = {{Raket, Lars Lau and Oudin Åström, Daniel and Norlin, Jenny M. and Kellerborg, Klas and Martinez-Martin, Pablo and Odin, Per}},
issn = {{2045-2322}},
language = {{eng}},
number = {{1}},
publisher = {{Nature Publishing Group}},
series = {{Scientific Reports}},
title = {{Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease}},
url = {{http://dx.doi.org/10.1038/s41598-021-04356-8}},
doi = {{10.1038/s41598-021-04356-8}},
volume = {{12}},
year = {{2022}},
}